Eli Lilly and Company (LLY) Stock Rating Reaffirmed by Jefferies Group LLC
Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group LLC in a report released on Monday. They currently have a $89.00 target price on the stock. Jefferies Group LLC’s price objective indicates a potential upside of 8.31% from the company’s previous close.
A number of other research analysts also recently issued reports on the stock. Piper Jaffray Companies restated an “overweight” rating and set a $105.00 target price (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. BMO Capital Markets restated an “underperform” rating and set a $71.00 target price (down from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Leerink Swann restated a “hold” rating on shares of Eli Lilly and in a research report on Thursday, August 31st. BidaskClub downgraded shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, Berenberg Bank restated a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company. Eli Lilly and currently has an average rating of “Hold” and an average target price of $88.07.
Eli Lilly and (NYSE:LLY) opened at 82.17 on Monday. The company has a 50-day moving average price of $80.93 and a 200-day moving average price of $82.06. The company has a market capitalization of $86.69 billion, a PE ratio of 35.56 and a beta of 0.34. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 earnings per share. Analysts expect that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Company (LLY) Stock Rating Reaffirmed by Jefferies Group LLC” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/13/eli-lilly-and-company-lly-stock-rating-reaffirmed-by-jefferies-group-llc.html.
In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 825,000 shares of company stock valued at $68,456,650. Insiders own 0.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Joel Isaacson & Co. LLC grew its stake in Eli Lilly and by 1.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after acquiring an additional 50 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Eli Lilly and by 7.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after acquiring an additional 48,706 shares in the last quarter. Stephens Inc. AR grew its stake in Eli Lilly and by 4.5% during the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after acquiring an additional 1,901 shares in the last quarter. Blair William & Co. IL grew its stake in Eli Lilly and by 13.1% during the 1st quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock valued at $21,974,000 after acquiring an additional 30,299 shares in the last quarter. Finally, Capital Advisors Inc. OK grew its stake in Eli Lilly and by 28.4% during the 1st quarter. Capital Advisors Inc. OK now owns 3,711 shares of the company’s stock valued at $312,000 after acquiring an additional 820 shares in the last quarter. 75.77% of the stock is owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.